Michael Okunewitch
Stock Analyst at Maxim Group
(0.82)
# 3,782
Out of 4,862 analysts
26
Total ratings
29.17%
Success rate
-17.77%
Average return
Main Sectors:
Stocks Rated by Michael Okunewitch
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| HCWB HCW Biologics | Maintains: Buy | $120 → $35 | $5.50 | +536.36% | 2 | May 29, 2025 | |
| CTOR Citius Oncology | Downgrades: Hold | n/a | $1.47 | - | 2 | May 23, 2025 | |
| ANEB Anebulo Pharmaceuticals | Maintains: Buy | $6 → $3 | $1.27 | +136.22% | 2 | May 15, 2025 | |
| RADX Radiopharm Theranostics | Initiates: Buy | $12 | $5.33 | +125.14% | 1 | May 1, 2025 | |
| CMMB Chemomab Therapeutics | Maintains: Buy | $4 → $7 | $1.22 | +473.77% | 2 | Feb 20, 2025 | |
| MYNZ Mainz Biomed | Initiates: Buy | $14 | $1.99 | +603.52% | 1 | Feb 14, 2025 | |
| LCTX Lineage Cell Therapeutics | Maintains: Buy | $5 → $3 | $0.70 | +327.05% | 1 | Jan 10, 2025 | |
| OCGN Ocugen | Initiates: Buy | $4 | $1.20 | +233.33% | 1 | Oct 15, 2024 | |
| FBLG FibroBiologics | Initiates: Buy | $12 | $0.87 | +1,275.36% | 1 | Sep 24, 2024 | |
| LGVN Longeveron | Maintains: Buy | $15 → $6 | $1.32 | +354.55% | 2 | Aug 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $3 → $12 | $1.02 | +1,076.47% | 2 | Mar 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $24 | $1.27 | +1,789.76% | 1 | Oct 5, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $108 → $18 | $3.12 | +476.92% | 3 | Aug 9, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $2,025 | $3.19 | +63,379.62% | 1 | Apr 12, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $25 | $20.35 | +22.85% | 1 | Dec 22, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $6 | $2.00 | +200.00% | 1 | Sep 28, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $25 | $2.18 | +1,046.79% | 1 | Nov 30, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $100 | $0.92 | +10,769.57% | 1 | Nov 30, 2021 |
HCW Biologics
May 29, 2025
Maintains: Buy
Price Target: $120 → $35
Current: $5.50
Upside: +536.36%
Citius Oncology
May 23, 2025
Downgrades: Hold
Price Target: n/a
Current: $1.47
Upside: -
Anebulo Pharmaceuticals
May 15, 2025
Maintains: Buy
Price Target: $6 → $3
Current: $1.27
Upside: +136.22%
Radiopharm Theranostics
May 1, 2025
Initiates: Buy
Price Target: $12
Current: $5.33
Upside: +125.14%
Chemomab Therapeutics
Feb 20, 2025
Maintains: Buy
Price Target: $4 → $7
Current: $1.22
Upside: +473.77%
Mainz Biomed
Feb 14, 2025
Initiates: Buy
Price Target: $14
Current: $1.99
Upside: +603.52%
Lineage Cell Therapeutics
Jan 10, 2025
Maintains: Buy
Price Target: $5 → $3
Current: $0.70
Upside: +327.05%
Ocugen
Oct 15, 2024
Initiates: Buy
Price Target: $4
Current: $1.20
Upside: +233.33%
FibroBiologics
Sep 24, 2024
Initiates: Buy
Price Target: $12
Current: $0.87
Upside: +1,275.36%
Longeveron
Aug 27, 2024
Maintains: Buy
Price Target: $15 → $6
Current: $1.32
Upside: +354.55%
Mar 5, 2024
Maintains: Buy
Price Target: $3 → $12
Current: $1.02
Upside: +1,076.47%
Oct 5, 2023
Initiates: Buy
Price Target: $24
Current: $1.27
Upside: +1,789.76%
Aug 9, 2023
Maintains: Buy
Price Target: $108 → $18
Current: $3.12
Upside: +476.92%
Apr 12, 2023
Initiates: Buy
Price Target: $2,025
Current: $3.19
Upside: +63,379.62%
Dec 22, 2022
Initiates: Buy
Price Target: $25
Current: $20.35
Upside: +22.85%
Sep 28, 2022
Initiates: Buy
Price Target: $6
Current: $2.00
Upside: +200.00%
Nov 30, 2021
Initiates: Buy
Price Target: $25
Current: $2.18
Upside: +1,046.79%
Nov 30, 2021
Initiates: Buy
Price Target: $100
Current: $0.92
Upside: +10,769.57%